GlassScriptPhysician profile
Scott A Luking
NPI 1912903188
$323.99
in general payments reported to CMS, 2019-2025
11 companies · $67.34 in 2025
The $67.34 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.88 · 2021: $16.18 · 2023: $116 · 2024: $50.62 · 2025: $67.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $54.69 | 2023-2024 | Wegovy, Ozempic |
| Scilex Pharmaceuticals INC. | $39.17 | 2019 | |
| Sunovion Pharmaceuticals INC. | $34.71 | 2019 | |
| Pfizer INC. | $34.27 | 2023 | |
| Mylan Specialty L.P. | $31.28 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $29.65 | 2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Daiichi Sankyo INC. | $29.52 | 2025 | Injectafer |
| Esperion Therapeutics, INC. | $19.70 | 2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.12 | 2025 | Caplyta |
| Exact Sciences Corporation | $16.70 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $16.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Luking listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.